Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

DOI Full Paper Access

35

Citations

18

References

2021

Year

Anja Gäckler, Ulf Schönermarck, Vladimir Dobronravov, Gaetano La Manna, Andrew Denker, Peng Liu, Maria Vinogradova, Sung Soo Yoon, Manuel Praga

Abstract

Clinical trial identifier: NCT02949128 .

References

	Year	Citations

Page 1